At present, in addition to blocking the immune checkpoints of the B7-CD28 family (such as PD1/PD-L1), anti-tumor immunity can also be augmented by biologics or genetic engineering techniques that modulate TNFSF/TNFRSF signaling [12, 13]. This evidence concerns the gene CD274 and neoplasm.